Video

Dr. Pegram on Developing Agents for Patients With HER2+ Breast Cancer and Brain Metastases

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses developing agents for patients with HER2-positive breast cancer who have brain metastases.

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses developing agents for patients with HER2-positive breast cancer who have brain metastases.

Nancy U. Lin, MD, showed a paper at the 2017 ASCO Annual Meeting looking at high doses of trastuzumab (Herceptin) after passing the first step of a Simon’s Two-Stage design. The 40-patient, randomized phase II PATRICIA trial has completed enrollment and results are pending. There are also new small-molecule HER2-targeted agents that are more specific to HER2. They don’t show as much toxicity as other drugs, such as lapatinib (Tykerb) or neratinib (Nerlynx).

Tucatinib (ONT-380) is a pure HER2-directed therapy that doesn’t inhibit EGFR. It doesn’t result in diarrhea and skin rash to the extent of existing FDA-approved HER2-targeted agents. That molecule is in an ongoing randomized registration trial. Additionally, recently published data on FDA-approved trastuzumab emtansine (TDM-1; Kadcyla) show anecdotal responses and high tolerability.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD